The Association of Hydroxychloroquine Dosing with Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus.
Alejandra Londono JimenezAna ValleMohammad Hashim MustehsanShudan WangJammie LawMaria Salgado GuerreroWenzhu B MowreyDaniel B HortonDavid BricenoAnna BroderPublished in: Arthritis care & research (2022)
Higher HCQ doses were not associated with an increased risk of HFrEF, life-threatening arrhythmia or cardiac death among patients with SLE and may decrease the risk among non-smokers. This article is protected by copyright. All rights reserved.